Jenner & Block

Martin C. Glass is co-chair of the firm’s Cross-Border Transactions Practice. He counsels U.S. and foreign companies in a wide array of transactional matters.

For nearly 20 years, Mr. Glass has focused on complex M&A and securities transactions. Domestic and foreign companies and their boards seek his assistance with structuring and negotiating public and private mergers, acquisitions, divestitures, public securities offerings, proxy contests, and other highly complex corporate transactions.

Mr. Glass also regularly counsels clients on continuous reporting and corporate governance requirements under the U.S. securities laws and the rules of the NYSE, NASDAQ and NYSE MKT.

Having advised clients on more than 100 closed M&A and securities transactions, Mr. Glass has experience in a variety of industries, including, life sciences, mining, energy and financial services.

Representative mergers and acquisitions engagements include the following:

  • Swiss-based Lonza Group Ltd. in its $5.5 billion acquisition of Capsugel S.A., a KKR + Co. L.P. portfolio company
  • Snyder’s-Lance, Inc. (Nasdaq: LNCE) in its $1.8 billion acquisition of Diamond Foods, Inc. (Nasdaq: DMND).
  • Japan-based THK Co. in its $400 million acquisition of the linkage and suspension business of TRW Automotive Holdings Corp.
  • Papillion Resources Ltd. in its $570 million sale to B2Gold Corp.
  • Richmont Mines Inc. (NYSE: RIC) in its announced $770 million sale to Alamos Gold Inc. (NYSE:AGI)

Representative securities and finance engagements include the following:

  • Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) in its $138 million initial public offering.
  • Lonza Group Ltd. in a $2.3 billion rights offering and in a $865 million common stock offering.
  • France Télécom S.A. in a sale via public offering of shares of a $1.5 billion interest in Telmex, the Mexican telecommunications company.
  • Stifel Nicolaus as lead underwriter for the initial public offering of Exa Corporation (Nasdaq: EXA).
  • Icade S.A., a leading French property developer, in its €710 million IPO.
  • Richmont Mines Inc. in its NYSE listing.
  • Theratechnologies Inc. in its Nasdaq listing.
  • Obagi Medical Products, Inc. in its $145 million follow-on public offering.
  • Tengion, Inc. a leader in the field of regenerative medicine, in its initial public offering.